Log in

Novus Therapeutics News Headlines (NASDAQ:NVUS)

$0.54
+0.02 (+3.85 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$0.51
Now: $0.54
$0.58
50-Day Range
$0.51
MA: $0.69
$0.79
52-Week Range
$0.50
Now: $0.54
$5.21
Volume97,266 shs
Average Volume59,057 shs
Market Capitalization$7.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86

Headlines

Novus Therapeutics (NASDAQ NVUS) News Headlines

Source:
DateHeadline
Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?
finance.yahoo.com - October 9 at 8:38 AM
Novus Therapeutics (NASDAQ:NVUS) vs. IntelGenx Technologies (NASDAQ:IGXT) Financial ComparisonNovus Therapeutics (NASDAQ:NVUS) vs. IntelGenx Technologies (NASDAQ:IGXT) Financial Comparison
www.americanbankingnews.com - October 6 at 2:01 PM
Novus Therapeutics to Participate in Two Upcoming Investor ConferencesNovus Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - August 29 at 11:03 AM
Novus Therapeutics Reports Second Quarter 2019 Financial ResultsNovus Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 13 at 6:48 PM
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB MarketAdynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
feeds.benzinga.com - July 22 at 7:42 AM
Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%
finance.yahoo.com - July 11 at 5:18 PM
Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis MediaNovus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
finance.yahoo.com - June 10 at 10:18 AM
Novus Therapeutics misses by $0.04Novus Therapeutics misses by $0.04
seekingalpha.com - May 14 at 7:05 PM
Novus Therapeutics Reports First Quarter 2019 Financial ResultsNovus Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 14 at 7:05 PM
Tuesday 5/7 Insider Buying Report: NLY, NVUSTuesday 5/7 Insider Buying Report: NLY, NVUS
www.nasdaq.com - May 8 at 9:29 AM
Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-MarketNovus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - May 2 at 6:36 PM
Equity offering pressures Novus, down 16%Equity offering pressures Novus, down 16%
seekingalpha.com - April 30 at 5:58 PM
Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-MarketNovus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - April 30 at 9:25 AM
Novus down 28% on underwhelming results for lead candidate in middle ear infectionNovus down 28% on underwhelming results for lead candidate in middle ear infection
seekingalpha.com - April 22 at 5:20 PM
Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical TrialsNovus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
finance.yahoo.com - April 22 at 9:18 AM
Novus Therapeutics IncNovus Therapeutics Inc
www.bloomberg.com - March 19 at 9:50 AM
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business WireNovus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business Wire
www.businesswire.com - February 20 at 9:48 AM
Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare ConferenceNovus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 20 at 9:48 AM
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
finance.yahoo.com - February 19 at 9:55 AM
Company Profile for Novus Therapeutics, Inc.Company Profile for Novus Therapeutics, Inc.
finance.yahoo.com - February 16 at 9:31 AM
Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
finance.yahoo.com - February 11 at 10:56 AM
Novus up 15% on advancement of OP0201Novus up 15% on advancement of OP0201
seekingalpha.com - January 31 at 5:34 PM
Novus Therapeutics Advances OP0201 Development Program Across Several Clinical TrialsNovus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
finance.yahoo.com - January 30 at 9:37 AM
Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
finance.yahoo.com - January 8 at 9:32 AM
Savara and CRISPR Therapeutics among healthcare gainers; EyePoint Pharmaceuticals and Novus Therapeutics among losers - Seeking AlphaSavara and CRISPR Therapeutics among healthcare gainers; EyePoint Pharmaceuticals and Novus Therapeutics among losers - Seeking Alpha
seekingalpha.com - December 25 at 4:31 PM
Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
finance.yahoo.com - December 25 at 4:31 PM
The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To DebutThe Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
feeds.benzinga.com - December 7 at 8:39 AM
Novus Therapeutics Announces Formation of Scientific Advisory BoardNovus Therapeutics Announces Formation of Scientific Advisory Board
finance.yahoo.com - December 4 at 9:33 AM
Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201 - Business WireNovus Therapeutics Doses First Subjects in Phase 1 Study of OP0201 - Business Wire
www.businesswire.com - November 28 at 9:43 AM
Novus Therapeutics (NVUS) Begins Dosing in Phase 1 Study of OP0201Novus Therapeutics (NVUS) Begins Dosing in Phase 1 Study of OP0201
www.streetinsider.com - November 27 at 4:26 PM
Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201
finance.yahoo.com - November 27 at 4:26 PM
Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare ConferenceNovus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference
finance.yahoo.com - November 15 at 9:16 AM
Form 8-K Novus Therapeutics, Inc. For: Nov 13Form 8-K Novus Therapeutics, Inc. For: Nov 13
www.streetinsider.com - November 13 at 9:03 AM
Novus Therapeutics Reports Third Quarter 2018 Financial ResultsNovus Therapeutics Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 13 at 9:03 AM
Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceNovus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 26 at 9:34 AM
Novus Therapeutics up 41% premarketNovus Therapeutics up 41% premarket
seekingalpha.com - September 7 at 9:20 AM
Novus readies stock offering; shares down 7% after hoursNovus readies stock offering; shares down 7% after hours
seekingalpha.com - September 5 at 9:31 AM
Novus Therapeutics Announces Proposed Public Offering of Common StockNovus Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 4 at 4:25 PM
Novus Therapeutics Reports Second Quarter 2018 Financial ResultsNovus Therapeutics Reports Second Quarter 2018 Financial Results
finance.yahoo.com - August 7 at 9:43 AM
Novus Therapeutics readies stock offering; shares down 5% premarketNovus Therapeutics readies stock offering; shares down 5% premarket
seekingalpha.com - August 1 at 11:06 AM
Novus shares rise 12% on FDA guidance for ear infection productNovus shares rise 12% on FDA guidance for ear infection product
www.marketwatch.com - June 19 at 11:21 AM
Novus on go with mid-stage study of OP-02 in otitis media; shares up 10% premarketNovus on go with mid-stage study of OP-02 in otitis media; shares up 10% premarket
seekingalpha.com - June 19 at 11:21 AM
Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis MediaNovus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
finance.yahoo.com - June 19 at 11:21 AM
Novus Therapeutics, Inc (NVUS) PT Raised to $7.50 at Ascendiant CapitalNovus Therapeutics, Inc (NVUS) PT Raised to $7.50 at Ascendiant Capital
www.streetinsider.com - April 9 at 9:43 AM
Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateNovus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - April 2 at 9:56 AM
Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?
finance.yahoo.com - January 6 at 9:06 AM
Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?Who Are The Largest Shareholders In Novus Therapeutics Inc (NVUS)?
finance.yahoo.com - November 22 at 6:19 AM
Novus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare ConferenceNovus Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 6:19 AM
Novus Therapeutics Reports Third Quarter 2017 ResultsNovus Therapeutics Reports Third Quarter 2017 Results
finance.yahoo.com - November 9 at 7:52 AM
Novus Therapeutics Announces the Promotion of Dr. Catherine Turkel to PresidentNovus Therapeutics Announces the Promotion of Dr. Catherine Turkel to President
finance.yahoo.com - November 7 at 7:58 AM
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel